1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Nerve Injury - Pipeline Review, H1 2016

Nerve Injury - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 73 pages

Nerve Injury - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Nerve Injury - Pipeline Review, H1 2016’, provides an overview of the Nerve Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Nerve Injury
- The report reviews pipeline therapeutics for Nerve Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nerve Injury therapeutics and enlists all their major and minor projects
- The report assesses Nerve Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nerve Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nerve Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Nerve Injury - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Nerve Injury Overview 8
Therapeutics Development 9
Pipeline Products for Nerve Injury - Overview 9
Pipeline Products for Nerve Injury - Comparative Analysis 10
Nerve Injury - Therapeutics under Development by Companies 11
Nerve Injury - Therapeutics under Investigation by Universities/Institutes 12
Nerve Injury - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Nerve Injury - Products under Development by Companies 15
Nerve Injury - Products under Investigation by Universities/Institutes 16
Nerve Injury - Companies Involved in Therapeutics Development 17
Acorda Therapeutics, Inc. 17
Biogen, Inc. 18
Caladrius Biosciences, Inc. 19
Calico LLC 20
F. Hoffmann-La Roche Ltd. 21
Human Stem Cells Institute 22
Kineta, Inc. 23
Kolon Life Science, Inc. 24
Medtronic plc 25
Neuralstem, Inc. 26
Neurotune AG 27
SanBio, Inc. 28
TissueGene, Inc. 29
Nerve Injury - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
3K3A-APC - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
cimaglermin alfa - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
CLP-257 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
KLS-Nst - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
MDT-15 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Neovasculgen - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
NSI-566 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
NT-1654 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
raxatrigine hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
SB-618 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Stem Cell Therapy for Sciatic Nerve Regeneration - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
TG-N - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
U-2902 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Nerve Injury - Recent Pipeline Updates 59
Nerve Injury - Dormant Projects 70
Nerve Injury - Discontinued Products 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development for Nerve Injury, H1 2016 9
Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Nerve Injury - Pipeline by Acorda Therapeutics, Inc., H1 2016 17
Nerve Injury - Pipeline by Biogen, Inc., H1 2016 18
Nerve Injury - Pipeline by Caladrius Biosciences, Inc. , H1 2016 19
Nerve Injury - Pipeline by Calico LLC, H1 2016 20
Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 21
Nerve Injury - Pipeline by Human Stem Cells Institute, H1 2016 22
Nerve Injury - Pipeline by Kineta, Inc., H1 2016 23
Nerve Injury - Pipeline by Kolon Life Science, Inc., H1 2016 24
Nerve Injury - Pipeline by Medtronic plc, H1 2016 25
Nerve Injury - Pipeline by Neuralstem, Inc., H1 2016 26
Nerve Injury - Pipeline by Neurotune AG, H1 2016 27
Nerve Injury - Pipeline by SanBio, Inc., H1 2016 28
Nerve Injury - Pipeline by TissueGene, Inc., H1 2016 29
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Stage and Target, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 34
Number of Products by Stage and Route of Administration, H1 2016 36
Number of Products by Stage and Molecule Type, H1 2016 38
Nerve Injury Therapeutics - Recent Pipeline Updates, H1 2016 59
Nerve Injury - Dormant Projects, H1 2016 70
Nerve Injury - Discontinued Products, H1 2016 71

List of Figures
Number of Products under Development for Nerve Injury, H1 2016 9
Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Top 10 Targets, H1 2016 31
Number of Products by Stage and Top 10 Targets, H1 2016 31
Number of Products by Top 10 Mechanism of Actions, H1 2016 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 33
Number of Products by Routes of Administration, H1 2016 35
Number of Products by Stage and Routes of Administration, H1 2016 35
Number of Products by Molecule Types, H1 2016 37
Number of Products by Stage and Molecule Types, H1 2016 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Dystrophin (DMD) - Pipeline Review, H2 2016

Dystrophin (DMD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Dystrophin (DMD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Dystrophin (DMD) - Pipeline Review, H2 2016’, provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.